11 reports of this reaction
1.4% of all ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE reports
#15 most reported adverse reaction
BREAST CANCER METASTATIC is the #15 most commonly reported adverse reaction for ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE, manufactured by Method Pharmaceuticals. There are 11 FDA adverse event reports linking ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE to BREAST CANCER METASTATIC. This represents approximately 1.4% of all 778 adverse event reports for this drug.
Patients taking ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE who experience breast cancer metastatic should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BREAST CANCER METASTATIC is a less commonly reported adverse event for ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE, but still significant enough to appear in the safety profile.
In addition to breast cancer metastatic, the following adverse reactions have been reported for ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE:
The following drugs have also been linked to breast cancer metastatic in FDA adverse event reports:
BREAST CANCER METASTATIC has been reported as an adverse event in 11 FDA reports for ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BREAST CANCER METASTATIC accounts for approximately 1.4% of all adverse event reports for ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE, making it a notable side effect.
If you experience breast cancer metastatic while taking ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.